THE DEAL, AT A GLANCE
From the announcementFORE Therapeutics
01What it doesFore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by European venture capital fund redalpine, new investors LongeVC, Oxford Science Enterprises, multiple investorsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedFORE Therapeutics raised $67.4M Series D, announced 2026-07-09From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersFORE Therapeutics' $67.4M Series D is a mid-market Healthcare & Life Sciences financing inside a highly active funding tape, positioning the company within continued…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
FORE Therapeutics · Financing Record
Explore source-linked visual explanations for FORE Therapeutics. Unsupported claims are withheld while source review continues.
Record 7887 · Recorded date: 2026-07-09
Explore company records →